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ABSTRACT
The association of HIV infection and hepatitis C virus (HCV) infection often occurs because both vi-
ruses share the same transmission routes, increasing the possibility of HIV/HCV coinfection. World 
prevalence greater than 30% of coinfected cases is estimated, and it can reach 90% depending on the 
transmission route. With the aim of determining the frequency and profi le of HIV/HCV coinfected 
patients, a descriptive analysis was carried out with patients with HIV/AIDS whose serology was 
positive for hepatitis C virus (HCV), cared for at the Fundação de Medicina Tropical do Amazonas 
from 2000 to 2007. In the present study, of the 2,653 AIDS cases notifi ed in SINAN, 1,582 patients 
underwent serology test for hepatitis C, and a frequency of 4.42% (n = 70) of HIV/HCV coinfected 
patients was identifi ed in the period studied. The most frequent infection route was sexual trans-
mission (84.3%), 68.6% among heterosexual individuals. Most patients were males (72.9%), aged 
between 25 and 40 years (60.1%), of low income (50% earning up to one minimum wage), and 
low educational level (80% had completed only middle school). A high percentage of deaths were 
observed during the study (34.3%). The results indicate a low seroprevalence of HIV/HCV coinfec-
tion in this population, in which sexual transmission, characterized by sexual promiscuity among 
heterosexual individuals, is the major transmission route of the virus rather than the use of injection 
drugs, as shown in world statistics. 
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INTRODUCTION
Hepatitis C virus (HCV) and human immu-
nodefi ciency virus (HIV) infections are among 
the ten major causes of death due to infectious 
diseases worldwide.1 Nowadays, there are more 
than 40 million HIV-infected individuals, 30% 
of whom are estimated to be also infected by 
HCV, representing a growing public health 
problem worldwide.2,3
Coinfection rates range from 4% to 90%, 
depending on the type of exposure. Studies 
carried out in Brazil have shown a coinfection 
prevalence of 40%, which varies according to 
region, geographic differences, age, and effi -
ciency of exposure.1,3,4,5
The HCV and HIV have similar transmis-
sion modalities, but the effi cacy of the trans-
mission of each virus differs, and several fac-
tors inﬂ uence that coinfection. For both, blood 
exposure and injection drug use are effi cient 
transmission forms. However, the risk of ver-
tical and perinatal transmissions is high for 
HIV and relatively low for HCV, although the 
risk increases twice when the mother is HIV 
positive.6,7 
The sexual transmission of HCV is inef-
fi cient, and the exact risk related to different 
types of sexual activity is unknown; neverthe-
less, it has been increasing among HIV-infected 
men who have sex with men (MSM).8
The introduction of highly active antiret-
roviral therapy (HAART) has signifi cantly 
improved life expectancy of HIV-infected pa-
tients; however, the consequences of hepatitis 
C have become more apparent, as a result ei-
ther of decompensated cirrhosis or hepatotox-
icity due to HAART.9,10,11 
The interaction of those viruses has been 
the object of great concern, being considered 
one of the most important public health prob-
lems faced by health professionals and authori-
ties worldwide.12
The present study aimed at determining the 
frequency of hepatitis C marker (anti-HCV) in 
a population of HIV patients notifi ed in the 
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SINAM database and cared for at the Fundação de Medicina 
Tropical do Amazonas (FMTAM) from 2000 to 2007. In ad-
dition, it also aimed at better knowing the profi le and be-
havior of this population, since epidemiological studies on 
HIV/HCV coinfection in the state of Amazonas are scarce.
MATERIAL AND METHODS
Description of the study area
This study was developed at FMTAM, a state reference 
center for the follow-up of HIV patients in the city of 
Manaus, home to approximately 1.71 million people of the 
2.8 million inhabitants of the state of Amazonas, 71.4% of 
whom are in urban areas and 28.6% in rural area.13
The FMTAM is one of the 20 testing and counseling 
centers of the state of Amazonas. It comprises specialized 
outpatient clinics, a hospitalization unit, and laboratories 
equipped for diagnosing infectious diseases. 
To identify the HIV and HCV coinfected population cared 
for at FMTAM from 2000 to 2007, the following databases 
were used: the SINAN (Sistema de Informações de Agravos 
de Notifi cação) database; the database of the Coordination of 
Sexually Transmitted Diseases/AIDS of the state of Amazo-
nas, and the database of the Virology Unit of FMTAM.
We chose to start the study in the year 2000 due to the 
lack of available data on viral hepatitis prior to that year. 
It is worth noting that, over the study period, the institu-
tion has undergone modernization of its outpatient clinics 
and laboratories, such as digitalization of patients’ data from 
2005, and integration with the information network of the 
Ministry of Health for AIDS cases. 
Study design
This is a descriptive study of a case series of patients with 
AIDS coinfected with HCV cared for at the FMTAM during 
the study period. After database cross-referencing and patients’ 
selection, medical records were sought for information referring 
to patients’ identifi cation, demographic data, socioeconomic 
and cultural profi les, as well as risk factors for the acquisition 
of the diseases in question. Those data were registered in a 
clinical-epidemiological form elaborated for the study.
Seventy patients were included in the study according to 
the following criteria: age over 12 years, both sexes, and posi-
tive serology for HIV (anti-HIV) and for HCV (anti-HCV). 
Patients with a positive marker for hepatitis B virus (HBsAg) 
and/or hepatitis D virus (anti-HD) and those who did not 
agree to participate in the study or sign the written informed 
consent were excluded.
This study has been approved by the Committee on 
Ethics in Research with Human Beings of FMTAM, un-
der protocol 2857/2007, in accordance with Resolution 
CNS 196/96 of the National Health Council of the Min-
istry of Health. 
Statistical analysis
The sample used for analysis comprised 70 HIV/HCV coin-
fected patients cared for at FMTAM from 2000 to 2007.
Data were presented using tables and graphs of simple, 
absolute, and relative frequencies. In the analysis of quan-
titative variables, mean and standard deviation (SD) were 
calculated. Data analysis used the Epi-Info software, version 
3.5 for Windows, developed and distributed by CDC (www.
cdc.gov/epiinfo). The 95% confi dence interval (CI) was 
adopted.
RESULTS
Origin of the coinfected population
According to SINAN, from 2000 to 2007, the total number 
of AIDS cases accumulated in Brazil corresponded to 
209,975 cases.14 In the Northern Region of Brazil, there 
were 8,903 cases, and in the state of Amazonas, 2,653 cas-
es, representing 1.3% of the total number of cases in the 
country.14
In terms of AIDS incidence, in the Brazilian northern 
region, the state of Amazonas is second only to the state of 
Pará. That population has a man to woman ratio of 2:1, a 
tendency that has been kept since 1999 in the state of Ama-
zonas, while in Brazil the current ratio is 1.5:1.14
During the period studied, 2,653 cases of AIDS were 
notifi ed at SINAN. Of those, only 1,582 patients had un-
dergone the serologic test for hepatitis C, 70 of which 
tested positive, representing a frequency of 4.42% of HIV/
HCV coinfected patients cared for at FMTAM during this 
period.
The HBV/HCV double infection was identifi ed in two 
patients, and the HBV/HCV/HDV triple infection was 
identifi ed in only one patient. These three patients were 
excluded from the study.
In Figure 1, the annual curve shows an increase in 
coinfection cases, from 1.45% in the year 2000 to 5.03% 
in 2007. 
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Figure 1: Annual distribution according to the frequency 
of HIV/HCV coinfected patients cared for at FMTAM from 
2000 to 2007. 
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Demographic data 
Regarding the gender of HIV/HCV coinfected population 
(n=70), men (n = 51, 72.9%) represented the majority. In 
this population, age ranged from 20 to 67 years (mean age, 
38.5 ± 10.2 years), with the age bracket of 30-35 years being 
the most populous (n = 20, 28.6%). Regarding the popula-
tion educational level, 80% (n = 56) had completed middle 
school, and 4.2% (n = 3) were illiterate. Regarding monthly 
income, 50% (n = 35) of the patients received up to one na-
tional minimum wage and 20% (n = 14) were unemployed.
Among the HIV/HCV coinfected patients, the place of 
birth of most patients (n = 39, 55.7%) was the city of Man-
aus, followed by the inner Amazonas state (n = 15, 21.4%), 
and other states (n = 16, 22.9%). Regarding the site of origin, 
94.3% (n = 66) came from the city of Manaus, only 5.7% 
(n = 4) from the inner Amazonas state, and nobody came 
from other states (Table 1).
Sexual orientation and risk factors
According to the sexual orientation of the patients studied, 
48 (68.6%) patients were heterosexual, 16 (22.8%) were ho-
mosexual, and six (8.6%) were bisexual. Fifty-nine (84.3%) 
patients have reported sexual promiscuity, that is, more than 
two partners in six months, and that was the major risk 
factor analyzed. Other risk factors were as follows: acquisi-
tion of sexually transmitted diseases (STD), reported by 33 
(47.1%) patients; sex partner known to have HIV infection, 
reported by 24 (34.3%) patients; and, in a lower proportion, 
use of injection drugs, reported by 15 patients (21.4%). 
Some patients had more than one risk factor associated 
at the same time (Table 2).
Evolution of coinfected patients
The coinfected patients detected in the period studied 
showed a high death rate (n = 24, 34.3%), with most deaths 
occurring between the years 2000 and 2003, and 46 (65.7%) 
patients were alive by the end of the study in December 2007 
(Table 2).
DISCUSSION
The epidemiology of AIDS has changed over the years in 
Brazil. This epidemic has shown its strength by spreading 
from the southeastern region to other regions in the coun-
try. In the northern region of Brazil, especially in the state 
of Amazonas, the epidemic has shown social, cultural, and 
geographic peculiarities.15
Almost fi ve years after its discovery, AIDS appeared in 
the state of Amazonas, and the fi rst notifi cation of the dis-
ease occurred in April 1986, when the notifi cation of AIDS 
cases in Brazil became compulsory.16 From 1986 to 1990, 
AIDS was restricted to the municipality of Manaus, and, 
from 1991, it spread to the inner state, but the city of Man-
aus still has the greatest number of notifi ed cases.14 
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Table 2. Distribution of HIV/HCV coinfected patients 
cared for at FMTAM from 2000 to 2007, according to 
sexual orientation, risk factors for coinfection, and 
outcome 
  Variables (n = 70) n %
Sexual orientation
 Heterosexual 48 68.6
 Homosexual 16 22.8 
 Bisexual 6 8.6
Partner with HIV infection 24 34.3
STDs 33 47.1
Use of injection drugs 15 21.4
> 2 partners in the past 6 months 59 84.3 
Death 24 34.3
Table 1. Distribution of HIV/HCV coinfected patients 
cared for at FMTAM from 2000 to 2007, according to 
demographic, socioeconomic, and cultural data
   Variables (n = 70) n  %
Gender
 Male 51 72.9
 Female 19 27.1 
Age (years)
 20 |--- 25 2 2.8
 25 |--- 30 9 12.9
 30 |--- 35 20 28.6
 35 |--- 40 13 18.6
 40 |--- 45 6 8.6
 45 |--- 50 8 11.4
 50 |--- 55 4 5.7
 55 |--- 60 6 8.6 
 ≥ 65 2 2.8
 Mean ± SD 38.5 ± 10.2
 Range 0 - 6
Educational level  
 Illiterate 3 4.3
 Complete middle school 6 80.0
 Complete high school 9 12.8
 Complete university 2 2.9 
Income (minimum wages)
 Unemployed 14 20.0
 ≤ 1 35 50.0
 2 to 3 16 22.9
 4 to 6 5 7.1
Place of birth
 City of Manaus 39 55.7
 Inner Amazonas state 15 21.4
 Other states 16 22.9
Origin
 City of Manaus 66 94.3
 Inner Amazonas state 4 5.7
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According to data from the Ministry of Health, the epi-
demic in the state of Amazonas seems to have had a tendency 
to increase with a progressive incidence rate until 1999, and 
stabilization from 2000 to 2003. It began to increase again 
from 2004, when an improvement in epidemiological surveil-
lance was observed with the restructuration of the State Coor-
dination of STD/AIDS Program in the state of Amazonas.14,15 
Nevertheless, the AIDS Epidemiological Surveillance 
system still suffers from sub-notifi cation of cases and delay 
in notifi cations.17,18 This may be one of the plausible justifi -
cations for the discrepancy observed between the cases noti-
fi ed in the state of Amazonas and the actual magnitude of 
the epidemic, as compared to the rest of the country.
In the population studied, a predominance of the male 
gender (72.9%) is observed, and this signifi cant difference 
between men and women is in accordance with the fi ndings 
of other studies carried out in Brazil,4,12,17,19 despite the ten-
dency of AIDS to increase among women.14,20
The population affected is young, at productive age, 
60.1% aged between 25 and 40 years, but already showing 
an increase in the age bracket as compared with the cases at 
the beginning of the AIDS epidemic.14 Our data are in ac-
cordance with the study by Pottes et al. (2007),17 who have 
also reported a large number of individuals (89.2%) with 
AIDS at that age bracket.
The educational level expresses differences between in-
dividuals in terms of access to information, and some pa-
rameters to reach better quality in prevention and health as-
sistance are undeniably directly linked to the socioeconomic 
level of the population, whose better indicators are educa-
tional level, income, and occupation.17
In Brazil, there was a tendency towards AIDS patients hav-
ing a higher educational level. In 1982, almost all cases were 
among individuals with university level or complete high 
school level, while only 24% of the cases were among illiterate 
individuals. An inversion in this trend has been observed since 
2000, with 74% of the cases informing the educational level 
were illiterate or had completed only middle school.21 
These data are consistent with those presented in our 
study, in which 80% of the patients included have only com-
pleted middle school, representing a low-income popula-
tion, 50% of whom receive up to one minimum wage, 20% 
are unemployed, and have a low educational level. 
In our study, most of the patients were born and came 
from the capital of the state of Amazonas, the city of 
Manaus, where the quality of life and access to information 
regarding disease prevention is directly related to the edu-
cational and socioeconomic level, essential factors involved 
in reducing the rates of the diseases in question, especially 
HIV infection.
The HIV/HCV coinfection rate of patients cared for at 
FMTAM was 2.6% (n = 70), and the world estimates, ac-
cording to some authors, have ranged from 4% to 90%, de-
pending on transmission route.22
In Brazil, the National Program of Control and Preven-
tion of Viral Hepatitis has estimated, based on studies al-
ready carried out in the country that the prevalence of HIV/
HCV coinfection ranges from 17% to 36% of the cases, var-
ying in different regions.23
Monteiro et al. (2004),24 studying 406 HIV-infected indi-
viduals in the city of Belém, in the state of Pará, have reported 
a 16% prevalence of HCV infection. Carvalho et al. (2009)25 
in the city of Recife, in the state of Pernambuco, studying 
the HIV/HCV coinfection have reported a low prevalence 
(4.1%) as compared with other studies in the literature, pos-
sibly due to differences in risk factors for acquiring HCV.
The high variability depends not only on the risk fac-
tors to which the population are exposed to, but also on the 
methods of HCV detection.26
In the present study, the major risk factor found was 
sexual transmission, characterized by sexual promiscu-
ity (84.3%), and STD acquisition (47.1%) between hetero-
sexual patients. This is in accordance with the studies by 
Szwarcwald (2000)27 and Amaral et al. (2007),4 who have 
also shown the predominance of coinfection among patients 
having heterosexual intercourse (68.6%) as compared with 
men having sex with men (MSM) (22.8%). 
The transmission modalities of HCV and HIV are 
known to be similar, but the transmission effi ciency of each 
virus differs. HCV transmission is more effi cient through 
exposure to contaminated blood or blood products, espe-
cially through the use of injection drugs.28 In certain high 
risk populations, such as users of injection drugs, coinfec-
tion is present in 72% to 95% of them.6,29,30
Similarly to the northeastern region of the country, in 
the northern region, the major drugs known to be used are 
cannabis and cocaine.12,17 The United Nations has reported 
Brazil as the second country with the highest number of 
individuals with HIV among drug users in Latin Ameri-
ca, in addition to being one of the major cocaine traffi c 
routes.31
A recent study carried out in the state of Pernam-
buco, in the northeastern region of Brazil, confirms our 
study, also showing a low prevalence of coinfected in-
dividuals in this state.25 The authors have reported that 
only 8.4% of the patients acquire HIV infection through 
the use of injection drugs, differently from the south-
eastern and southern regions, whose rates are 25.8% and 
30.7%, respectively. They have not found a positive rela-
tion between coinfection and the use of injection drugs, 
in accordance with our study, in which the drug-injec-
tion use rate was only 21.4%.25
Despite the small number of HIV/HCV coinfected pa-
tients (4.42%) in our study, the annual distribution accord-
ing to the frequency showed an ascending curve, ranging 
from 1.45% in the year 2000 to 5.03% in 2007. 
Such fi ndings emphasize the possibility that gradual in-
crease results from the improvement in notifi cation of AIDS 
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cases, from the investigation of hepatitis cases in those pa-
tients over the years, and from the longer survival of AIDS 
patients due to the use of the HAART regimen introduced 
in 1996.
It is worth noting that the deaths in our study (34.3%) oc-
curred mainly between the years 2000 and 2003, when the cause 
of death could not be attributed to the presence of HCV.
Our study can have underestimated the actual prevalence 
of coinfection in the population studied due to the existence 
of ﬂ oatation in the serologic status and even seroconversion 
(the anti-HCV turns negative), which are 2.5 times more 
frequent among HIV/HCV coinfected patients as compared 
with HCV mono-infected patients.32 
In anti-HCV positive immunosuppressed patients, HCV 
RNA should be investigated, and its presence confi rms the 
diagnosis; however, a negative result does not exclude HCV 
infection, and, whenever suspicion is high, a new investiga-
tion should be performed in six months.33,34 
However, in some active HCV infections, HCV RNA 
cannot be detected. This can occur in individuals whose 
anti-HCV antibody levels are high, and RNA levels are low.35 
Thus, HCV RNA cannot be detected in certain individuals 
in the acute phase of hepatitis C, but such fi ndings are tran-
sient and a chronic infection can develop.36
The low HIV/HCV coinfection rate (4.42%) found in 
our study as compared to that of other regions can be at-
tributed not only to the small size of the sample, but also to 
the fact that HCV infection and diagnosis are still increasing 
in the region. 
On the other hand, serological tests are known to have 
lower sensitivity in the immunodefi ciency scenario, and 
polymerase chain reaction (PCR) is required for confi rming 
the diagnosis.
The present study suggests that larger studies are re-
quired for better assessing the profi le of this population 
and the prevalence of HIV/HCV coinfection in the state 
of Amazonas. The present study also stresses the need for 
early investigation of hepatitis C in HIV patients by using 
both serologic and molecular methods, because the litera-
ture emphasizes the impact of HIV in patients with HCV, 
regarding the rapid liver disease progression and evolution 
to death. 
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